Develops drugs for rare eye diseases.
Dec 2025Revenue $0.00/yrExpenses $39.2M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will KALA BIO be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $39.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $39.2M | −$39.2M |
| Dec 2024 | $0.00 | $41.0M | −$41.0M |
| Dec 2023 | $0.00 | $39.7M | −$39.7M |
| Dec 2022 | $3.89M | $85.6M | −$81.7M |
| Dec 2021 | $11.2M | $141M | −$130M |
| Dec 2020 | $6.36M | $103M | −$96.2M |
| Dec 2019 | $6.07M | $94.3M | −$88.2M |
| Dec 2017 | $0.00 | $39.9M | −$39.9M |
| Dec 2016 | $0.00 | $32.7M | −$32.7M |
| Dec 2015 | $45.0K | $16.0M | −$15.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.